People who have never used the word “appendix” in a medical sentence now know someone with appendix cancer. Young adults are showing up with colorectal tumors that used to belong to their grandparents. Physicians who spent careers calling certain malignancies “rare” are saying the word less often, and with less confidence.
That observation does not require a conspiracy board. The registries already show it. Appendix cancer in the United States rose 232% between 2000 and 2016. Americans born in the early 1980s are several times more likely to receive that diagnosis than Americans born in the 1940s. Colorectal cancer in people ages 20 to 49 is climbing about 3% a year while it falls in the elderly. Carcinoma rates in adolescents and young adults have been drifting upward for decades. In 2026 the National Cancer Institute still reports that overall cancer deaths are falling. Incidence is another story, especially in the young, and especially in tumors that used to be footnotes.
What the observation does not do is hand the public a finished cause. Obesity, ultra-processed food, childhood antibiotics, lockdowns that postponed screening, better detection, and the virus itself are all in the pile. So are the products that a handful of corporations, armed with federal liability shields and captured regulators, rolled out to the entire population in 2021 and then boosted, and boosted again.
The companies prefer that sentence to end before their names appear. A free country is not required to oblige them.
The Record the Defendants Do Not Want Sliced
The product was authorized, mandated, and marketed before anyone had years of follow-up on cancer. Manufacturers were protected under the PREP Act. Injury claims were steered into the Countermeasures Injury Compensation Program, not a courtroom with discovery. Former FDA commissioners later collected millions from the same manufacturers whose products they had overseen. Scott Gottlieb left the agency and sat on Pfizer’s board.
That is not a scientific finding. It is corporatism: the state supplies coercion and immunity; the firm supplies the inventory, talking points, and of course the money.
In 2025 a South Korean analysis of roughly 8.4 million health-insurance records reported higher one-year risks after vaccination for thyroid, gastric, colorectal, lung, breast, and prostate cancer. Hazard ratios ran from about 1.20 to 1.69. The journal later attached an expression of concern. An Italian provincial cohort found a modest rise in cancer hospitalization among the vaccinated that vanished when the lag from shot to diagnosis was stretched to twelve months. Early-onset appendix and colorectal charts were already moving before the first EUA.
None of that is a closed case for the defense. None of it is a closed case for the prosecution. It is what you get when the one party with the money and the statutory shield also gets to decide which tables are published. Dose, product, and date of injection should have been standard cuts of every cancer registry on earth. They were not. That omission is not an accident of paperwork. It is the business model.
Repeated boosting was sold as maintenance. It was an experiment in how many times a healthy population can be re-stimulated without a long ledger. Immune surveillance against damaged cells is not a slogan. It is a daily function. A platform given to hundreds of millions of people who were not sick was never a vitamin. Treating every unanswered question as a threat to “confidence” was never science. Confidence is a sales term.
They Answered Before the Data Did
Operation Warp Speed and the EUA process transferred development risk from shareholders to the public. Mandates transferred the remaining uncertainty onto workers, soldiers, students, and parents. Networks that live on pharmaceutical advertising treated dissent as contamination. Agencies that later employed, or were later paid by, the manufacturers defined the boundary of acceptable speech. When a Korean paper showed a signal, the reflex was not “replicate it.” The reflex was “concern.” When oncologists said they were seeing stranger disease in younger people, the reflex was to police the vocabulary.
That is how corporatism handles a medical mystery. It does not have to prove the product is safe. It only has to make the cost of asking higher than the cost of swallowing the press release.
A free market in medicine would look different. The firm that wants to inject a new platform into hundreds of millions of healthy arms would carry the liability. Regulators would not rotate onto the board. Cancer registries would be sliced by dose, product, and date of injection as a matter of course, not as a favor. Until that happens, “trust the science” means trust the defendants.
Rare cancers do not seem so rare anymore. Delayed screening will explain some of the catch-up diagnoses. It will not explain a twenty-year climb in tumors of the young. Diet will explain some of that climb. It does not entitle Pfizer, Moderna, and their regulators to a lifetime gag order.
If the shots contributed even a sliver to the change in what oncologists now call rare, the public will not learn it from a manufacturer press office. It will learn it the way every other industrial injury is eventually learned: against the will of the people who profited. Until the liability shield comes off and the raw, dose-dated registries are public, the correct posture is not comfort. It is unfinished business.
Look at the age of the patients. Look at who cannot be sued. Then decide how rare you still think this is.
